Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin + Gemcitabine + Nab-Paclitaxel in Advanced Pancreatic Cancer
NCT05947825Phase 2Enrolling by invitation
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitagliptin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival up to 2 years. Started Jul 2023; status: enrolling by invitation.
02
Drugs
sitagliptin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05947825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05947825.